What is ocular surface squamous neoplasia?
Ocular surface squamous neoplasia, usually shortened to OSSN, is a group of growths that arise from the flat (squamous) cells covering the surface of the eye. These cells form the outer layer of the conjunctiva, the clear membrane over the white of the eye, and of the cornea, the clear window at the front of the eye.
OSSN covers a spectrum of disease. At the mild end, abnormal cells stay within the surface layer; this is called conjunctival or corneal intraepithelial neoplasia, a precancerous stage. At the other end is invasive squamous cell carcinoma, where cancer cells have broken through into the deeper tissue. Most people are diagnosed somewhere along this range.
OSSN is the most common non-pigmented tumour of the eye surface (Monroy et al., 2023). It mainly affects older people, especially men and those with a lot of sun exposure (Basti and Macsai, 2003). In parts of Africa, it is also common in younger adults living with HIV.
Most OSSN appears as a pink, jelly-like or white patch near the edge of the cornea. When it is found early, it can usually be cured with eye drops or minor surgery, and the eye and vision are preserved.
1. Key facts at a glance
| Feature | Details |
|---|---|
| What it is | A spectrum from precancerous change to squamous cell carcinoma of the eye surface |
| Also called | Conjunctival squamous cell carcinoma; conjunctival intraepithelial neoplasia (CIN) for the early stage |
| How common | The most frequent non-pigmented tumour of the ocular surface |
| Typical age | Usually over 60; younger with HIV |
| Main risk factors | Sunlight, older age, male sex, smoking, HIV, HPV |
| Usual site | Limbus, where the cornea meets the white of the eye |
| Main treatments | Topical chemotherapy drops, or surgical excision with cryotherapy |
| Outlook | Excellent for early disease; recurrence possible |
2. Types of OSSN
| Type | Description | Behaviour |
|---|---|---|
| Mild dysplasia (CIN I) | Abnormal cells in the lower third of the surface layer | Precancerous |
| Moderate dysplasia (CIN II) | Abnormal cells in up to two-thirds of the layer | Precancerous |
| Severe dysplasia or carcinoma in situ (CIN III) | Abnormal cells through the full thickness, but not beyond | Precancerous, high grade |
| Invasive squamous cell carcinoma | Cancer cells invade below the surface layer | Can spread locally and, rarely, further |
| Aggressive variants | Mucoepidermoid and spindle cell carcinomas | More likely to invade the eye or orbit |
Appearance patterns
| Pattern | Description |
|---|---|
| Gelatinous | Translucent, jelly-like, pink or grey |
| Papillary | Raised with small finger-like projections and red dots of vessels |
| Leukoplakic | White, chalky surface from keratin |
| Nodular | A raised lump; more likely to be invasive |
| Diffuse | Spreads flatly and can be mistaken for conjunctivitis |
How OSSN compares with other eye surface growths
| Growth | Key features |
|---|---|
| Pinguecula | Yellowish, flat or slightly raised; benign |
| Pterygium | Wing-shaped tissue growing onto the cornea; benign |
| Conjunctival papilloma | Benign, often HPV-related, usually in younger people |
| Conjunctival melanoma | Usually pigmented; a different cancer |
| OSSN | Gelatinous, papillary or white; often at the limbus; may have feeder vessels |
3. Causes and risk factors
| Risk factor | Notes |
|---|---|
| Ultraviolet (UV) light | The main environmental factor; more common near the equator |
| Older age | Risk increases with age |
| Male sex | Men are affected more often |
| Fair skin | Higher risk with sun-sensitive skin |
| Smoking | Increases the risk |
| HIV infection | Raises the risk by about eight times (Carreira et al., 2013) |
| Human papillomavirus (HPV) | A possible contributor; the evidence is strongest for certain HPV types |
| Immune suppression | After organ transplantation, for example |
| Xeroderma pigmentosum | A rare inherited condition with extreme UV sensitivity |
A meta-analysis found a strong link with HIV. The evidence on HPV was more mixed, with the clearest association involving cutaneous (skin-type) HPV strains (Carreira et al., 2013).
Anyone diagnosed with OSSN at a young age, especially in regions where HIV is common, is usually offered an HIV test.
4. How does it look
On the eye
| Feature | Description |
|---|---|
| Colour | Pink, red, grey or white |
| Texture | Gelatinous, velvety or warty |
| Position | Usually at the limbus, in the part of the eye exposed between the lids |
| Blood vessels | Enlarged feeder vessels and small looped vessels within the lesion |
| Cornea | A grey, frosted sheet spreading over the cornea in some cases |
On imaging
High-resolution anterior segment optical coherence tomography (OCT) gives a cross-section of the eye surface. OSSN shows a thickened, bright surface layer with a sharp change from normal tissue. This test helps with diagnosis and with monitoring during treatment with eye drops (Monroy et al., 2023).
Under the microscope
| Feature | Description |
|---|---|
| Dysplasia | Disordered, enlarged cells within the surface layer |
| Carcinoma in situ | Full-thickness abnormal cells with an intact base |
| Invasive carcinoma | Nests of cancer cells below the basement membrane |
| Keratin | May form pearls in well-differentiated tumours |
Impression cytology, where a small filter paper is pressed on the eye to collect surface cells, can also support the diagnosis without surgery (Basti and Macsai, 2003).
5. Symptoms
Common symptoms
- A visible growth or patch on the white of the eye or at the edge of the cornea
- Redness in one area that does not settle
- Irritation, grittiness or a feeling of something in the eye
- Watering
Less common symptoms
| Symptom | What it may mean |
|---|---|
| Blurred vision | Growth over the cornea |
| Pain | Deeper invasion or inflammation |
| Restricted eye movement or bulging | Rarely, spread into the eye socket |
| Lump in front of the ear or in the neck | Rarely, lymph node spread |
When to seek medical advice
See an optician or eye doctor if you notice a new growth on the eye, or redness or irritation in one spot that lasts more than a few weeks. Persistent “conjunctivitis” on one side, especially in older people, should be checked.
6. Diagnosis
| Test | Purpose |
|---|---|
| Slit-lamp examination | Magnified view of the eye surface |
| Photographs | Record the lesion for comparison |
| Anterior segment OCT | Non-invasive cross-sectional imaging |
| Impression cytology | Collects surface cells without cutting |
| Biopsy or excision | Confirms the diagnosis and depth |
| Ultrasound biomicroscopy | Checks for invasion into the eye |
| CT or MRI of the orbit | If spread into the eye socket is suspected |
| HIV test | Recommended, especially in younger people |
Staging
Invasive conjunctival carcinoma is staged with the TNM system:
| Component | What it describes |
|---|---|
| T (tumour) | Size and invasion of nearby structures, such as the eyelid, the eye itself or the orbit |
| N (nodes) | Spread to lymph nodes in front of the ear or under the jaw |
| M (metastasis) | Distant spread, which is rare |
7. Treatment
Topical chemotherapy (eye drops)
Over the past two decades, eye drops have become a main alternative to surgery. A meta-analysis found that topical treatment and surgical excision gave similar resolution and recurrence rates (Kozma et al., 2022).
| Drug | How it is used | Notes |
|---|---|---|
| Interferon alfa-2b | Drops several times a day for months | Gentle; few side effects; slower to work |
| 5-fluorouracil (5-FU) | Drops in cycles, for example one week on and three weeks off | Effective; mild to moderate irritation |
| Mitomycin C | Drops in short cycles | Very effective but more toxic; often second line |
Interferon and 5-FU are often chosen first because they are well tolerated, while mitomycin C is kept for cases that do not respond (Monroy et al., 2023).
Surgery
| Step | Purpose |
|---|---|
| “No-touch” excision with wide margins | Removes the tumour without spreading cells |
| Alcohol to the corneal part | Lifts away abnormal surface cells |
| Cryotherapy (freezing) to the edges | Destroys microscopic cells left at the margins |
| Grafting | Amniotic membrane or conjunctiva covers the wound |
Surgery is often preferred for nodular or suspected invasive tumours, sometimes combined with drops before or after.
Choosing between drops and surgery
| Consideration | Drops may suit | Surgery may suit |
|---|---|---|
| Size and spread | Large or diffuse lesions covering much of the surface | Small, well-defined lesions |
| Suspected invasion | Less suitable | Preferred, so the tissue can be examined |
| Diagnosis | Made by OCT or cytology | Confirmed by the removed tissue |
| Effect on the eye surface | Treats the whole surface, including hidden cells | Can leave scarring or dryness |
| Commitment | Weeks to months of regular drops | A single procedure plus short recovery |
| Cost and access | Some drugs are costly or hard to obtain | Requires an eye surgeon and theatre time |
Many specialists combine the two, for example using drops to shrink a large lesion before surgery, or after surgery to treat any remaining abnormal cells.
How eye drops are used safely
Chemotherapy eye drops are powerful medicines. Store them as instructed, often in the fridge. Keep them away from children and avoid touching the bottle tip to the eye. Wash your hands after use.
Your doctor may also suggest pressing gently on the inner corner of the eye for a minute after each drop, to limit drainage into the tear duct.
Advanced disease
| Situation | Treatment |
|---|---|
| Invasion into the eye | Radiotherapy (plaque brachytherapy), or removal of the eye |
| Invasion into the orbit | Orbital exenteration, sometimes with radiotherapy |
| Lymph node spread | Neck or parotid surgery, radiotherapy |
| Unresectable or metastatic disease | Immune checkpoint inhibitors are being explored |
Side effects
| Treatment | Possible side effects |
|---|---|
| Interferon drops | Mild redness, flu-like symptoms with injections |
| 5-FU drops | Redness, stinging, watering, lid irritation |
| Mitomycin C | Pain, redness, damage to the surface cells and tear duct narrowing |
| Surgery and cryotherapy | Dry eye, scarring, discomfort |
In the meta-analysis, dry eye was the most frequent side effect overall and was reported in more than half of patients after surgery (Kozma et al., 2022).
What treatment involves day to day
| Stage | What to expect |
|---|---|
| Starting drops | Instructions on dosing, handling and storage |
| During treatment | Clinic checks every 4-8 weeks with photos or OCT |
| Surgery | A day-case procedure under local or general anaesthetic |
| After surgery | Antibiotic and steroid drops for a few weeks |
8. Outlook (prognosis)
| Situation | Usual outlook |
|---|---|
| Intraepithelial neoplasia | Excellent; usually cured with drops or excision |
| Small invasive carcinoma | Very good with complete treatment |
| Recurrence | Possible, especially with positive margins or large lesions |
| Invasion of the eye or orbit | Less common; may require major surgery |
| Spread to lymph nodes or beyond | Rare |
Recurrences are more likely in people with HIV, large lesions, corneal involvement or incomplete removal.
9. Follow-up
| Follow-up | Purpose |
|---|---|
| Eye examinations every 3-6 months at first | Checks for recurrence |
| Photographs and OCT | Detect early regrowth |
| Yearly checks long term | Recurrence can occur years later |
| Examination of the other eye | OSSN can occur in both eyes |
| Lymph node checks | For invasive tumours |
10. Living with OSSN
- Wear UV-blocking sunglasses and a brimmed hat outdoors
- Use drops exactly as instructed, and wash your hands before and after
- Use lubricating drops for dryness
- Stop smoking
- Attend HIV care regularly if you are living with HIV
- Report new redness or growth promptly
11. Frequently asked questions
| Question | Answer |
|---|---|
| Is OSSN cancer? | It ranges from precancerous change to squamous cell carcinoma |
| Will I lose my eye? | Very rarely; most people keep their eye and vision |
| Can drops cure it without surgery? | Often yes, especially for non-invasive disease |
| Is it caused by the sun? | Sunlight is a major factor, along with age, smoking and infections |
| Why was I offered an HIV test? | HIV greatly increases the risk, and treatment of HIV helps outcomes |
| Can it come back? | Yes, so regular checks are needed |
| Does it spread? | Spread beyond the eye is rare |
| Can I wear contact lenses? | Usually not during treatment; ask your eye doctor |
12. Questions to ask your care team
- Is my OSSN intraepithelial or invasive?
- Would eye drops or surgery suit me better?
- Which drug do you recommend, and how long will treatment last?
- What side effects should I watch for?
- How often will I need check-ups?
- Should I have an HIV test?
Resources
- Basti, S. and Macsai, M.S. (2003) ‘Ocular surface squamous neoplasia: a review’, Cornea, 22(7), pp. 687-704.
- Carreira, H. et al. (2013) ‘HIV and HPV infections and ocular surface squamous neoplasia: systematic review and meta-analysis’, British Journal of Cancer, 109(7), pp. 1981-1988.
- Kozma, K. et al. (2022) ‘Topical pharmacotherapy for ocular surface squamous neoplasia: systematic review and meta-analysis’, Scientific Reports, 12(1), 14221.
- Monroy, D. et al. (2023) ‘Medical treatment for ocular surface squamous neoplasia’, Eye, 37(5), pp. 885-893.
Prepared by the editorial team, October 2026.